Related Experiment Video
Updated: Jun 8, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Endpoints of hepatitis B treatment
1Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA.
Journal of Viral Hepatitis
|September 16, 2010
Summary
Hepatitis B treatments aim to prevent liver disease progression. This review examines intermediate endpoints, like blood markers, to assess treatment effectiveness and determine therapy duration, as long-term outcomes take years to develop.
Area of Science:
- Hepatology
- Virology
- Clinical Trials
Background:
- Hepatitis B infection can lead to severe liver conditions such as cirrhosis, liver failure, and hepatocellular carcinoma.
- Long-term clinical endpoints for hepatitis B therapies take many years to manifest, complicating treatment evaluation.
- Clinical trials necessitate reliable intermediate endpoints to assess treatment efficacy and guide therapeutic decisions.
Purpose of the Study:
- To review the validity of intermediate endpoints used in hepatitis B clinical trials.
- To assess the utility of biochemical, histological, virological, and serological markers as surrogates for long-term clinical outcomes.
- To discuss the rates of achieving these intermediate endpoints with current hepatitis B therapies.
Main Methods:
- Literature review of clinical studies and trials in hepatitis B treatment.
- Analysis of intermediate endpoints (biochemical, histological, virological, serological) used in hepatitis B research.
- Evaluation of the correlation between intermediate endpoints and established clinical outcomes.
Main Results:
- Intermediate endpoints are crucial for evaluating hepatitis B treatment efficacy in the short term.
- The validity of various intermediate endpoints as surrogates for clinical outcomes requires careful consideration.
- Current hepatitis B therapies show varying success rates in achieving these intermediate endpoints.
Conclusions:
- Intermediate endpoints serve as vital surrogates for long-term clinical outcomes in hepatitis B treatment trials.
- Further research is needed to refine and validate the most effective intermediate endpoints for hepatitis B therapy.
- Optimizing the use of intermediate endpoints can accelerate the evaluation of new hepatitis B treatments.
More Related Videos
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...